Derui Medical: Received the administrative supervision measures decision from Jilin Securities Regulatory Bureau.

Derui Medical Announcement: On February 5, 2026, the company received a decision from the Jilin Securities Regulatory Bureau regarding the "Decision on Taking Corrective Measures against Derui Medical Technology Co., Ltd. and Issuing Warning Letters to Wang Xuemin, Niu Dandan, and Zhang Xingyan." Upon investigation, it was found that the company had been careless in recognizing foreign sales order revenue, resulting in an overstatement of operating income by 3.693 million RMB and an overstatement of operating profit by 716,000 RMB in 2023. Additionally, the company's internal controls for foreign sales were found to be inadequate, with some related documentation being incomplete. The Jilin Securities Regulatory Bureau has decided to impose corrective administrative supervision measures on the company, and issue warning letters to the then General Manager Wang Xuemin, Deputy General Manager Niu Dandan, and CFO Zhang Xingyan.